Komodo Health, Inc. is a privately held healthcare intelligence company founded in 2014 and headquartered in New York, NY, with additional offices in San Francisco. It provides real-world data analytics through its Healthcare Map platform, which aggregates de-identified patient records to analyze disease patterns, treatment outcomes, and related metrics primarily for life sciences organizations.
The company employs AI-driven tools to deliver insights from claims, clinical, and other data sources. It remains independent with a valuation exceeding $3 billion and has made acquisitions such as Mavens in 2021 to expand its enterprise software capabilities.
Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.
Real‑world claims analysis found semaglutide 2 mg escalation gave similar HbA1c <7% rates and higher ≥5% weight‑loss rates than switching to titratable tirzepatide.
